Methods and compositions for reducing or eliminating post-surgical adhesion formation

• US 7,202,281 B2
• Filed: 12/31/2003
• Issued: 04/10/2007
• Est. Priority Date: 07/11/1996
• Status: Expired due to Fees

• Current Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Hebrew University of Jerusalem)
• Original Assignee: Synthemed, Inc. (Pathfinder Cell Therapy, Inc.)
• Inventors: Cohn, Daniel, Pines, Eli, Hotovely, Anna
• Primary Examiner(s): Webman; Edward J.
• Application Number:
  US10/749,436
• Publication Number:
  US 20040156819A1
• Time in Patent Office: 1,196 Days
• Field of Search: 514/772.1, 525/424, 525/43, 525/449, 525/454, 525/408
• US Class Current: 514/772.1
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/77 of oxiranes
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: C08G 63/08 Lactones or lactides
• CPC Class Codes: C08G 63/664 derived from hydroxy carboxylic acids
• CPC Class Codes: C08G 69/44 Polyester-amides
• CPC Class Codes: C08L 67/025 containing polyether sequences
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C08L 77/12 Polyester-amides

Abstract

The present invention relates to a method for reducing adhesions associated with post-operative surgery. The present method comprises administering or affixing a polymeric composition preferably comprising chain extended, coupled or crosslinked polyester/poly(oxyalkylene) ABA triblocks or AB diblocks having favorable EO/LA ratios to a site in the body which has been subjected to trauma, e.g. by surgery, excision or inflammatory disease. In the present invention, the polymeric material provides a barrier to prevent or reduce the extent of adhesions forming.

Claims

1. A composition for use in reducing adhesions in a patient according to the structure:

2. The composition according to claim 1 wherein K is a C₁ to C₁₂ alkyl group, an aryl group, an aralkyl group or a substituted C₁ to C₁₂ alkyl group, a substituted aryl group, a substituted aralkyl group, a C═

C—

containing group.

3. The composition according to claim 1 where K is methyl or ethyl.

4. The composition according to claim 1 wherein j is 0.

5. The composition according to claim 1 wherein R₁ is CH₃.

6. The composition according to claim 1 wherein R is exclusively ethylene.

7. The composition according to claim 1 wherein R′

is a poly(ethylene oxide) rich chain.

8. The composition according to claim 1 wherein R′

is a 2,2,4-trimethylhexamethylene group.